{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:50:53Z","timestamp":1792605053806,"version":"4.5.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study compared persistence of patients initiating rimegepant versus oral triptans for the acute treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort analysis was conducted using US MarketScan claims data (1 March 2019 to 30 June 2023) among commercially- and US federal Medicare-insured migraine patients initiating rimegepant or oral triptans. Persistence was defined as having \u22651 refill within 12 months of initial prescription and was compared between propensity score-matched rimegepant and triptan cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Before matching, 13,599 patients were identified in the rimegepant cohort and 38,127 in the triptan cohort. After matching, each cohort included 9909 patients. Significantly more rimegepant patients were persistent (75.8%) versus triptan patients (53.5%) (odds ratio [OR] 2.72, 95% confidence interval [CI] 2.56\u20132.90). Subgroup analyses showed similar trends for rimegepant versus specific triptans (rizatriptan: OR 2.49 [95% CI 2.33\u20132.67], and sumatriptan: OR 2.92 [95% CI 2.73\u20133.12]) and in patients with chronic migraine (OR 2.86 [95% CI 2.53\u20133.23]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides compelling evidence that rimegepant is associated with greater persistence than oral triptans for real-world acute treatment of migraine. Rimegepant is a favorable option for patients seeking effective and tolerable long-term treatment, particularly for those with insufficient response, intolerability, or contraindications to triptans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251352849","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:43:24Z","timestamp":1753685004000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-6638","authenticated-orcid":false,"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"The New England Institute for Neurology and Headache, Stamford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-9388","authenticated-orcid":false,"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Tadworth, Surrey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1599-4696","authenticated-orcid":false,"given":"Carl","family":"Henriksen","sequence":"additional","affiliation":[{"name":"Henriksen Analytic Insights, LLC, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-6863","authenticated-orcid":false,"given":"Feng","family":"Dai","sequence":"additional","affiliation":[{"name":"Pfizer Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8635","authenticated-orcid":false,"given":"Jo","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Pfizer Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-8621","authenticated-orcid":false,"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Tadworth, Surrey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[{"name":"Praxis Gendolla, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241252666"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1744806918767697"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0696-8"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1214"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S24752"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420915167"},{"key":"e_1_3_3_10_2","unstructured":"Pfizer Inc. NURTEC ODT prescribing information. New York NY: Pfizer Inc 2025."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01753-y"},{"key":"e_1_3_3_12_2","article-title":"Reduction in period prevalence of medication overuse headache following initiation of nurtec ODT treatment \u2013 a real world administrative claims study (P12-2.003)","author":"L\u2019Italien GJ","unstructured":"L\u2019Italien GJ, Harris L, Mohajer A, et al. Reduction in period prevalence of medication overuse headache following initiation of nurtec ODT treatment \u2013 a real world administrative claims study (P12-2.003). Neurology 2022; 98: 3698.","journal-title":"Neurology"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000559"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01813-3"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3043"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_3_3_17_2","first-page":"143","article-title":"Rimegepant 75 MG, an oral calcitonin gene-related peptide antagonist, for the acute treatment of migraine: two phase 3, double-blind, randomized, placebo-controlled trials","volume":"38","author":"Lipton RB","year":"2018","unstructured":"Lipton RB, Coric V, Stock EG, et al. Rimegepant 75 MG, an oral calcitonin gene-related peptide antagonist, for the acute treatment of migraine: two phase 3, double-blind, randomized, placebo-controlled trials. Cephalalgia 2018; 38: 143\u2013144.","journal-title":"Cephalalgia"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221141686"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00576-4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/175063"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02451-x"},{"key":"e_1_3_3_23_2","article-title":"Patient-reported outcomes in acute migraine management: a prospective, real-world, longitudinal study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant","volume":"64","author":"Lipton R","year":"2024","unstructured":"Lipton R, Parikh K, Gao X, et al. Patient-reported outcomes in acute migraine management: a prospective, real-world, longitudinal study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant. Headache 2024; 64.","journal-title":"Headache"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12404"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14854"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2410930"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080107","article-title":"Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis","volume":"386","author":"Karlsson WK","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. Br Med J 2024; 386: e080107.","journal-title":"Br Med J"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411433042"},{"key":"e_1_3_3_31_2","first-page":"82","article-title":"Real-world treatment experience and satisfaction among migraine patients: a descriptive survey study","volume":"62","author":"Smith TR","year":"2022","unstructured":"Smith TR, Hubig L, Williams E, et al. Real-world treatment experience and satisfaction among migraine patients: a descriptive survey study. Headache 2022; 62: 82\u201383.","journal-title":"Headache"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01343.x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000204267"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251352849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251352849","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251352849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:57Z","timestamp":1777387617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251352849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/03331024251352849"],"URL":"https:\/\/doi.org\/10.1177\/03331024251352849","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"03331024251352849"}}